Dr. Jean Michel Brunel | Microbiology | Research Excellence Award
CRHC | Faculty of Pharmacy | France
Dr. Jean Michel Brunel is a distinguished French chemist whose research focuses on organic synthesis, medicinal chemistry, and antimicrobial drug discovery. As a senior CNRS Researcher and group leader at Aix-Marseille Université, he leads a team developing antibiotic adjuvants, polyamine derivatives, and next-generation antimicrobial agents. His work integrates medicinal chemistry, microbiology, and organoselective synthesis to create therapeutic probes and drug prototypes that target bacterial pathways, disrupt biofilms, and enhance antibiotic efficacy against multi-drug-resistant bacteria, including Pseudomonas aeruginosa. Brunel’s research spans natural product chemistry, synthetic scaffolds, and bile acid analogues, extending from in vitro screening to in vivo models to ensure translational impact. Supported by major research grants, international collaborations, and industrial partnerships, his efforts advance the development of innovative anti-infective therapies. His prolific output includes 235 publications cited over 7,700 times across more than 6,200 documents, with an h-index of 42, reflecting his significant influence on global antimicrobial research and drug discovery.
Profiles: Scopus | ORCID | Google Scholar
Featured Publications
Permeabilize, but choose wisely: Selective antibiotic potentiation through outer membrane disruption in Pseudomonas aeruginosa. International Journal of Molecular Sciences.
Adaptation to cinnamaldehyde shapes Pseudomonas aeruginosa resistance to major antibiotics. Journal of Bacteriology.
Accurate antibiotic accumulation in Enterobacteriaceae isolates expressing efflux pumps. Biochimica et Biophysica Acta Biomembranes.
Don’t miss out on new publications by this author!
Bioinspired syntheses of the marine pyridoacridine alkaloids 2-Bromo and 3-Bromodeoxyamphimedine and structure correction of 2-Bromoamphimedine. Journal of Natural Products.
Efflux-mediated resistance in Enterobacteriaceae: Recent advances and ongoing challenges to inhibit bacterial efflux pumps.
Uric acid, the end-product of purine metabolism, mitigates tau-related abnormalities: Comparison with DOT, a non-antibiotic oxytetracycline derivative. Biomolecules.